Endocrine Abstracts

Abstract unavailable....

Sustained mineralocorticoid receptor (MR) signalling promotes cardiac inflammation and fibrosis, which ultimately leads to cardiac failure. While the clinical use of MR antagonists are protective in cardiac disease, hyperkaelemia, and other off target effects have limited their use. In order to identify key MR-dependent mechanisms of heart disease progression that are distinct to normal renal electrolyte control, we have developed a series of tissue selective MR null animal mo...

Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure (HF), reduced ejection fraction (REF) with severe symptoms (RALES, spironolactone) or with mild symptoms (EMPHASIS-HF, eplerenone), and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction (MI) (EPHESUS, eplerenone). These clinical benefits are observed in addition to those of angiotensin-converting enzyme (ACE...